AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & ...

Caidya and Simbec-Orion have united to create a new platform aimed at helping drug development programs accelerate and scale.

Boehringer Ingelheim has landed an exclusive license to Prime Vector Technologies’ (PVT) viral vector platform for developing ...

As Novo Nordisk looks for new ways to broaden its semaglutide GLP-1 franchise, the Danish drugmaker has signed a new deal ...

Biocytogen and Whitehawk Therapeutics are joining forces to develop bispecific antibody-drug conjugates (ADCs) using ...

MeiraGTx has secured an investment of up to $400 million from Oberland Capital to help get its late-stage gene therapies | As ...

As U.S. lawmakers continue to scrutinize the consequences of China’s expanding role in biotech innovation, industry insiders ...

Diagnostics specialist Beckman Coulter has expanded its portfolio of Alzheimer’s disease diagnostics by earning a ...

Clinical-stage biotech Kalohexis is preparing for a public listing to support its obesity and cancer cachexia treatments. | ...

Phase 3 trials of Kailera Therapeutics’ oral GLP-1 prospect have hit their primary endpoints, positioning the biotech’s ...

Women in England are set to gain new, taxpayer-funded tests for endometriosis after NICE recommended them for regular use. | ...

Novartis is pushing deeper into antibody-drug conjugate (ADC) development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload. Switzerland’s Novartis largely stayed ...